Blood pumping can predict kidney cancer 5 years in advance

have found a marker in the blood that can help predict a human risk of kidney cancer, according to a study published in the journal
on Monday.
the study compared the blood of 190 patients with secondary kidney cancer using a sample from the EPIC study. It was found that by measuring the levels of protein molecules in the blood, known as KIM-1, it was expected that a person would be more likely to develop kidney cancer within the next five years. Also, the higher the KIM-1 concentration, the higher the risk of kidney cancer and the lower the survival rate.
this, scientists believe that in future medical diagnoses, doctors could use THE-1 level test in the blood with medical imaging to diagnose kidney cancer or help rule out other diseases.
, kidney cancer is the 7th most common cancer in the UK and cases are on the rise. In the UK, 25% of kidney cancer patients are diagnosed with advanced stages. If a patient is diagnosed early in kidney cancer, 80% of patients survive for 5 years or more.
, early diagnosis has the potential to significantly improve the survival rate of patients with kidney cancer. However, most cancer patients do not develop any symptoms at an early stage, and many cases have found a range of other health conditions in medical imaging observations.
"s study has taken a big step forward, with KIM-1 levels the only blood markers that can predict people at high risk of kidney cancer and those at low risk. Next, we need to look more closely to see if KIM-1 levels can help detect benign tumors, as well as tumors at an early stage. It also looked at whether the blood marker could be used as a tool to track a patient's condition. "Dr David Muller, from Imperial College and funded by Cancer Research UK.
Charles Swanton, chief clinician at Cancer Research UK, said: "The potential for blood testing for cancer detection and surveillance is becoming increasingly apparent, and this work is further evidence that they can be a powerful tool in clinical practice".
, the medical community urgently needs to shift the diagnosis of kidney cancer to an early stage, and treatment for kidney cancer is more likely to be successful, and this study is moving toward that goal. But the researchers also note that since the study is still in its infancy, forward-looking studies of a wider population are needed before the method can be widely used in clinical practice.
, from Harvard Medical School and funded by the National Institutes of Health, said: "What is critical now is how to incorporate KIM-1 level testing into patient treatments through a deeper understanding. In addition, the postoperative rehabilitation of patients with KIM-1 level kidney cancer should be further observed. (Source: Ma Chen, China Science Daily)